We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.65 | -1.80% | 35.50 | 35.65 | 35.95 | 36.35 | 35.75 | 36.15 | 1,182,891 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 210.88 | 193.64M |
TIDMAPH
RNS Number : 4885M
Alliance Pharma PLC
28 July 2017
For immediate release 28 July 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Update on Diclectin
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that it has been advised by the UK's regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), that the marketing authorisation submission for Diclectin has not been approved.
Diclectin, a treatment for nausea and vomiting of pregnancy, was in-licensed from Duchesnay Inc. of Canada ("Duchesnay") for the UK in 2015 and for a further nine European territories in 2016. The total amount paid to Duchesnay for all territories was GBP1.5 million.
Whilst this is disappointing news, this will have no material impact on the Company's expected near-term results.
Certain information contained in this announcement constituted inside information (as defined by Article 7 of the Market Abuse Regulation) prior to the dissemination of this announcement.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief Executive Officer Peter Butterfield, Deputy Chief Executive Officer Andrew Franklin, Chief Financial Officer + 44 (0) 20 7466 Buchanan 5000 Mark Court / Sophie Cowles + 44 (0) 20 7260 Numis Securities Limited 1000 Nominated Adviser: Michael Meade / Freddie Barnfield Corporate Broking: James Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUUPMUPMGAR
(END) Dow Jones Newswires
July 28, 2017 11:21 ET (15:21 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions